MedTrace Logo

Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals

NCT01040104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2013-11-13

No results posted yet for this study

Summary

Regular wound healing follows a well-ordered sequence of overlapping phases: inflammation, proliferation, maturation and remodelling.

In the young, damage to an organ mostly triggers fully regenerative mechanisms called "primary" wound healing. Repeated damage in young individuals may cause "secondary" wound healing eg. scar formation reflecting a rescue program, in which reorganisation has failed.

Organ failure in the ageing organism is characterized by a progressive loss of its capability to achieve an orderly reactivation of organ repair, and results in a combination of chronic inflammation and fibroproliferative, non-regenerative repair affecting several organs, including lung, liver and skin.

RESOLVE's objective is to identify, characterize, and validate molecular targets responsible for shifting primary organ repair towards fibroproliferative wound healing as a result of an age-dependent loss of regulatory control.

The structured approach is based on

* different forms of wound healing,
* different human diseases and
* different genetic backgrounds,

aiming to provide future diagnostic tools in various organs, to create transgenic animal test systems, and to identify molecular targets involved in fibroproliferative wound healing.

Conditions

Interventions

OTHER

Skin sample

Taken from regularly discarded tissue during routine operation

OTHER

Skin biopsy

Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90

OTHER

Skin biopsy

Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90

OTHER

Blood taking

Blood taking on day 0

OTHER

Blood taking

Blood taking on day 90

Sponsors & Collaborators

  • European Union

    collaborator OTHER

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Lars P Kamolz, MD, MSc · MUW

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-07-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01040104 on ClinicalTrials.gov